Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1961 1
1963 1
1974 2
1975 4
1976 7
1977 14
1978 16
1979 25
1980 47
1981 58
1982 65
1983 54
1984 71
1985 60
1986 55
1987 58
1988 82
1989 104
1990 130
1991 130
1992 148
1993 143
1994 149
1995 154
1996 151
1997 145
1998 132
1999 150
2000 145
2001 139
2002 179
2003 183
2004 132
2005 160
2006 157
2007 173
2008 167
2009 165
2010 191
2011 214
2012 229
2013 222
2014 231
2015 240
2016 249
2017 234
2018 253
2019 278
2020 209
Text availability
Article attribute
Article type
Publication date

Search Results

5,940 results
Results by year
Filters applied: . Clear all
Page 1
Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy.
Goossens JF, Bailly C. Goossens JF, et al. Pharmacol Ther. 2019 Nov;203:107396. doi: 10.1016/j.pharmthera.2019.107396. Epub 2019 Jul 26. Pharmacol Ther. 2019. PMID: 31356908 Review.
Ursodeoxycholic acid (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. ...
Ursodeoxycholic acid (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid b
Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G, Beuers U. Paumgartner G, et al. Hepatology. 2002 Sep;36(3):525-31. doi: 10.1053/jhep.2002.36088. Hepatology. 2002. PMID: 12198643 Review.
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests three major mechanisms of action: (1) protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, resulting from modulat
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence sugges
Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.
Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Guarino MP, et al. World J Gastroenterol. 2013 Aug 21;19(31):5029-34. doi: 10.3748/wjg.v19.i31.5029. World J Gastroenterol. 2013. PMID: 23964136 Free PMC article. Review.
Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic acid (UDCA), demonstrating its extreme versatility. ...
Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic
Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases?
Keely SJ, Steer CJ, Lajczak-McGinley NK. Keely SJ, et al. Am J Physiol Gastrointest Liver Physiol. 2019 Dec 1;317(6):G872-G881. doi: 10.1152/ajpgi.00163.2019. Epub 2019 Sep 11. Am J Physiol Gastrointest Liver Physiol. 2019. PMID: 31509435 Review.
The secondary bile acid ursodeoxycholic acid (UDCA) has long been known to have medicinal properties. As the therapeutically active component of bear bile, it has been used for centuries in traditional Chinese medicine to treat a range of conditions, while ma …
The secondary bile acid ursodeoxycholic acid (UDCA) has long been known to have medicinal properties. As the therapeuti …
Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.
Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, Holvoet T, Vilchez-Vargas R, Vital M, Pieper DH, Vanden Bussche J, Vanhaecke L, Van de Wiele T, De Vos M, Laukens D. Van den Bossche L, et al. Appl Environ Microbiol. 2017 Mar 17;83(7):e02766-16. doi: 10.1128/AEM.02766-16. Print 2017 Apr 1. Appl Environ Microbiol. 2017. PMID: 28115375 Free PMC article.
However, the exact mechanism by which bile acid therapy confers protection from colitogenesis is currently unknown. Since the gut microbiota plays a crucial role in the pathogenesis of IBD, and exogenous bile acid administration may affect the community structure of …
However, the exact mechanism by which bile acid therapy confers protection from colitogenesis is currently unknown. Since the gut mic …
Neuroprotective strategies for retinal disease.
Pardue MT, Allen RS. Pardue MT, et al. Prog Retin Eye Res. 2018 Jul;65:50-76. doi: 10.1016/j.preteyeres.2018.02.002. Epub 2018 Feb 23. Prog Retin Eye Res. 2018. PMID: 29481975 Free PMC article. Review.
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. Fickert P, et al. J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18. J Hepatol. 2017. PMID: 28529147 Free article. Clinical Trial.
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C(23) homologue of UDCA and has shown potent anti-cholestatic, …
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical t …
UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D, Arab JP, Arrese M. Cabrera D, et al. Handb Exp Pharmacol. 2019;256:237-264. doi: 10.1007/164_2019_241. Handb Exp Pharmacol. 2019. PMID: 31236688 Review.
., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the present review, we summarize current experimental and clinical data regarding these BAs and its role in the treatment of certain liver dise …
., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the …
A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid.
He XL, Wang LT, Gu XZ, Xiao JX, Qiu WW. He XL, et al. Steroids. 2018 Dec;140:173-178. doi: 10.1016/j.steroids.2018.10.009. Epub 2018 Oct 31. Steroids. 2018. PMID: 30389306
A novel synthetic route of producing ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) was developed through multiple reactions from cheap and readily-available cholic acid. ...In the straightforward synthetic route for preparation of UDCA and OCA …
A novel synthetic route of producing ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) was developed through multi …
5,940 results
Jump to page
Feedback